¿Cómo paga?

Cómo pagar lo menos posible

Lo administra su equipo médico

Lo factura la clínica

Opdivo lo administra un médico o una enfermera; no se recoge en una farmacia.

Qué hacer

  1. Antes de su cita, pregunte a su equipo médico o a su plan cuánto pagaría.

Su equipo médico y su seguro deciden qué producto recibe.

Compare todas las opciones

De marca

Opdivo, el original

Sin seguroPregunte en la farmacia
Formas de ahorrar en Opdivo

La tarjeta del fabricante

BMS Access Support Co-Pay Assistance Program

Tarjeta de ahorro de Bristol Myers Squibb

Sin seguroRequiere seguroNo tiene precio sin seguro.
Con seguro $0 por dosis

Inscríbase en bmsaccesssupport.com 

O llame al 1-800-861-0048.

En palabras del fabricante (en inglés)

“$0 Co-pay per dose…”

De la oferta del fabricante en bmsaccesssupport.com, revisada el 17 de noviembre de 2026. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.

Genérico autorizado

No existe ninguno.

No se vendeNo existe ninguno

Genérico regular

Opdivo es un medicamento biológico. Los biológicos no tienen genéricos, pero algunos tienen biosimilares o una versión sin marca del mismo fabricante. Pregúntele a su farmacéutico o a su médico si se vende alguno.

No se vendePregunte en la farmacia

Para qué se usa

Lo que dice la etiqueta de la FDA (en inglés)

OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:

Melanoma

  • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab.
  • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.

Non-Small Cell Lung Cancer (NSCLC)

  • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
  • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery.
  • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab.
  • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy.
  • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Malignant Pleural Mesothelioma

  • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab.

Renal Cell Carcinoma (RCC)

  • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab.
  • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib.
  • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.

Classical Hodgkin Lymphoma (cHL)

  • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD).
  • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after:
    • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or
    • 3 or more lines of systemic therapy that includes autologous HSCT.

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy.

Urothelial Carcinoma

  • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.
  • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
  • adult patients with locally advanced or metastatic urothelial carcinoma who:
    • have disease progression during or following platinum-containing chemotherapy.
    • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Colorectal Cancer

  • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.
  • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Hepatocellular Carcinoma (HCC)

  • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab.
  • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib.

Esophageal Cancer

  • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
  • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1).
  • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1).
  • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma

  • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.

Fuente: la etiqueta de la FDA de Opdivo (E.R. Squibb & Sons, L.L.C.), 12 de agosto de 2026. Etiqueta completa en DailyMed 

Datos útiles

  • “Seguro comercial” quiere decir un plan de su trabajo, del Mercado de Seguros Médicos o uno que usted compra por su cuenta. Un plan para jubilados que forma parte de Medicare cuenta como Medicare. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.
  • La mayoría de las tarjetas requieren inscribirse en el sitio web del fabricante, y muchas solo funcionan si su plan cubre el medicamento. Después, dé los datos de la tarjeta a la oficina de facturación de la clínica.
  • No deje ni cambie un medicamento sin hablar con su farmacéutico o su médico.